High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis

Abstract

High-throughput metabolite quantification, with new systemic biomarkers, improved risk stratification for subclinical atherosclerosis in comparison to conventional lipids and could potentially be useful for early cardiovascular risk assessment.

Lipoprotein subclass metabolism in nonalcoholic steatohepatitis

“…The details of this methodology have been described previously ( 13,19 ), and this platform has recently been applied in various large-scale epidemiological and genetic studies (20)(21)(22). The lipoprotein subclass data available are as follows: chylomicrons and largest VLDL particles (average particle diameter at least 75 nm); fi ve different VLDL subclasses: very large VLDL (average particle diameter of 64.0 nm), large VLDL (53.6 nm), medium VLDL (44.5 nm), small VLDL (36.8 nm), and very small VLDL (31.3 nm); IDL (28.6 nm); three LDL subclasses: large LDL (25.5 nm), medium LDL (23.0 nm), and small LDL (18.7 nm); and four HDL subclasses: very large HDL (14.3 nm), large HDL (12.1 nm), medium HDL (10.9 nm), and small HDL (8.7 nm).…”

A metabolic view on menopause and ageing

“…Qi et al 47 have recently established a novel risk locus for coronary heart disease among diabetic patients, located in the GLUL gene. The mechanisms by which alterations 48 , and glutamine concentration, has been positively associated with higher intimamedia thickness of carotid artery as well as with coronary artery atherosclerosis 49 . The same study also linked tyrosine concentrations with these two CVD-related end points.…”

Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy

“…In another study, HDL-P, but not HDL-C, was inversely associated with carotid intima-media thickness after adjusting for covariates ( 12 ). Moreover, the use of NMR-derived lipoprotein subclasses improved risk stratifi cation for subclinical atherosclerosis in comparison to conventional lipids ( 13 ). Altogether, these and other evidence have precipitated two signifi cant events: 1 ) the 510(k) clearance from the US Food and Drug Administration (FDA) to market the Vantera Supplemental Material can be found at:…”